The 2019 Award of 50’000.00 Swiss Francs has been granted on November 28, 2020 in Lugano to
Jean-Yves BLAY, MD, PhD
in recognition for his contribution to the understanding and treatment of sarcoma.
Professor Jean-Yves Blay, MD is a medical oncologist, General Director of the Centre Leon Berard, the Comprehensive Cancer Centre of Lyon France, researcher and a Professor at the University Claude Berard, France. Since 2019, he is the President of the French Federation of Cancer Centers Unicancer.
His work focuses on sarcoma, genomics and targeted treatment of cancer, immune-oncology, and the relationship between tumour immunologic microenvironment and malignant cells, with the goal of clinical applications in the field of diagnosis, prognosis and treatment.
He has been distinguished with the Hamilton-Fairly award from ESMO (European Society for Medical Oncology) (2012) and the Henry and Mary-Jane Mitjaville prize from the National Academy of Medicine (2013).
Professor Blay is the Subject Editor for Sarcoma and Gastrointestinal Stromal Tumors for the ESMO Guidelines Committee, and the Director of ERN-EURACAN (European network for rare adult solid cancers), designated by the EU Commission in 2016 to improve the quality of care for patients with rare cancers in the European Union.
He is also the President of the French Sarcoma Group, the Network Leader of NETSARC (French clinical reference network for soft tissue and visceral sarcomas) sarcoma treatment reference centres, and a member of the ESMO EU Policy Committee and the ESMO Principles of Clinical Trials and Systematic Therapy Faculty.
Previously, he served as the President of EORTC (European Organisation for Research and Treatment of Cancer) between 2009 and 2012 and the former Principal Investigator of Conticanet, an EU Commission network of excellence.
Professor Blay has co-authored over 700 peer-reviewed articles and book chapters, has an H Index of 100 and was distinguished as Highly Cited Researcher in 2019.
He advises various national and international institutions and research organisations, and is an active member of several oncological organisations and societies, such as ESMO, ASCO (American Society of Clinical Oncology) and AACR (American Association for Cancer Research). He was the scientifc chair of the ESMO Congress 2019.
The San Salvatore Foundation, with its base in Lugano, Switzerland, was created in 1979 by Carlo Pernsch, a well known banker, and his wife Célestine with the purpose of promoting and rewarding medical and scientific research in the area of antitumor therapies.
For over 40 years the San Salvatore Foundation has recognized with its awards numerous scientists who have contributed in a substantial manner to the scientific research on new approaches to antitumor therapeutics and has provided grants for scientific projects for the cure of malignant diseases.